Congress Should Lower Insulin Costs by Addressing Pricing Abuses in Addition to Capping Co-Pays

Our outrageous insulin cost problem
Unlike all other advanced countries, the United States has never had the ability to negotiate drug prices federally and as a result, insulin prices have increased 50% or more in five years. There is no justification for these extreme price increases - they are purely the result of price gouging by manufacturers.

Egregious insulin pricing abuses are not only expensive, they are also dangerous for people who need insulin. Individuals who require insulin have been forced to make unconscionable financial decisions between buying this lifesaving drug and purchasing other basic needs, like food. This means some are forced to turn to rationing their insulin due to high costs, sometimes at the risk of their own lives.¹ ²

In the U.S.

- About 7.4 million people rely on insulin
- 1 in 10 people skip or ration insulin due to cost
- 1 in 4 low-income people skip or ration insulin due to cost

What Congress has done
Passed the Inflation Reduction Act: Capping out-of-pocket cost of insulin at $35 per month for those who get health care through Medicare. The bill also created for the first time a pathway for the federal government to negotiate fair drug prices, though insulin does not qualify for negotiation under the bill’s eligibility criteria.

What Congress should do next
1. Reduce the price that Medicare pays for insulin. The current insulin cap means Medicare is paying higher burden without manufacturer price reductions.³
2. Cap the out-of-pocket cost of insulin at $35 per month for people who do not have coverage through Medicare.

Undoubtedly, a cap for insulin means important relief from burdensome out-of-pocket costs for many families, but such a cap does not address the large-scale issue: Taxpayers are still paying manufacturers too much for this drug. Additionally, a cap does not help people who rely on insulin and do not have health insurance. Sixty eight percent of people without health insurance pay the full list price for insulin at the counter, compared with 9% of people with private insurance and 3% of Medicaid beneficiaries. Consequently, 38% of people without health coverage report being unable to afford prescription medicines, compared with 10% of people with private insurance.⁴
Don't stop at caps, fix the underlying unfair high prices

Congress should act to improve access to insulin for Americans who do not access health care through Medicare. It should not give into monopolistic special interests and simply cap the out-of-pocket cost of insulin without negotiating fair drug prices with insulin manufacturers. If that were to happen, the anti-competitive insulin cartel could continue to gouge U.S. taxpayers by charging prices that are several times higher than what the rest of the world pays, and continue arbitrarily increasing drug prices. Taxpayers, employers, and working people would continue to bear the cost of the outrageous price increases for insulin. We all pay that cost in our private and Medicare insurance premiums now, and we are passing that cost on to the next generation as it adds to our budget deficit.

If Congress passes a cap on out-of-pocket costs for insulin without negotiating manufacturer prices for insulin, many individuals and families would be blind to future price increases. As a result, many Americans might not be aware enough to voice their outrage at the high and rising cost of lifesaving insulin. Instead, they would unknowingly pay for the cost of these pricing abuses through health insurance premiums and future tax burdens.

Conclusion

Addressing the rising costs of insulin is essential, and Congress has already taken important first steps toward helping families afford the lifesaving and life-sustaining drug. Now American families deserve Congress’ full commitment to taking a comprehensive approach to fixing this problem. Passing caps on out-of-pocket costs for insulin without addressing manufacturers’ arbitrarily high prices will not solve the whole problem. Insulin manufacturers should be held accountable for making reasonable and justifiable price increases, and American families should be able to afford the insulin they need.

For endnotes see familiesusa.org/LowerInsulinCosts.